Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Items 1-10 of 19

Page
per page
  1. AG957
    C5826 AG957
    Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
  2. GNF-7
    B6033 GNF-7
    Summary: Type II Bcr-Abl inhibitor
      insoluble in EtOH; insoluble in H2O; ≥5.48 mg/mL
  3. PD 166326
    C3677 PD 166326
    Summary: receptor tyrosine kinases inhibitor
      ≤25 mg/mL
  4. Nilotinib monohydrochloride monohydrate
    A3660 Nilotinib monohydrochloride monohydrate
    Summary: Bcr-Abl inhibitor
      ≥50 mg/mL
  5. Dasatinib (BMS-354825)
    A3017 Dasatinib (BMS-354825)
     4 Citation
    Summary: Src and BCR-Abl inhibitor
      ≥24.4 mg/mL
  6. Nilotinib(AMN-107)
    A8232 Nilotinib(AMN-107)
     1 Citation
    Target: Bcr-Abl
    Summary: Bcr-Abl kinase inhibitor,selective
      ≥26.5 mg/mL
  7. Bosutinib (SKI-606)
    A2149 Bosutinib (SKI-606)
     1 Citation
    Target: Bcr-Abl|Src
    Summary: Potent Abl/Src kinases
      ≥26.5 mg/mL
  8. Imatinib Mesylate (STI571)
    A1805 Imatinib Mesylate (STI571)
    Target: PDGFR|c-Kit|Bcr-Abl
    Summary: Abl/c-kit/PDGFR inhibitor
      ≥29.5 mg/mL
  9. Saracatinib (AZD0530)
    A2133 Saracatinib (AZD0530)
     3 Citation
    Target: Src
    Summary: Src/Abl inhibitor,potent and selective
      ≥27.1 mg/mL
  10. Ponatinib (AP24534)
    A5467 Ponatinib (AP24534)
     1 Citation
    Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src
    Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor
      ≥53.3 mg/mL

Items 1-10 of 19

Page
per page